BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Peters HP, Laarakkers CM, Swinkels DW, Wetzels JF. Serum hepcidin-25 levels in patients with chronic kidney disease are independent of glomerular filtration rate. Nephrology Dialysis Transplantation 2010;25:848-53. [DOI: 10.1093/ndt/gfp546] [Cited by in Crossref: 67] [Cited by in F6Publishing: 69] [Article Influence: 5.2] [Reference Citation Analysis]
Number Citing Articles
1 Campostrini N, Traglia M, Martinelli N, Corbella M, Cocca M, Manna D, Castagna A, Masciullo C, Silvestri L, Olivieri O, Toniolo D, Camaschella C, Girelli D. Serum levels of the hepcidin-20 isoform in a large general population: the Val Borbera study. J Proteomics 2012;76 Spec No.:28-35. [PMID: 22951294 DOI: 10.1016/j.jprot.2012.08.006] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 2.3] [Reference Citation Analysis]
2 den Elzen WP, de Craen AJ, Wiegerinck ET, Westendorp RG, Swinkels DW, Gussekloo J. Plasma hepcidin levels and anemia in old age. The Leiden 85-Plus Study. Haematologica 2013;98:448-54. [PMID: 23065507 DOI: 10.3324/haematol.2012.068825] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 2.5] [Reference Citation Analysis]
3 van Swelm RPL, Wetzels JFM, Swinkels DW. The multifaceted role of iron in renal health and disease. Nat Rev Nephrol 2020;16:77-98. [PMID: 31554933 DOI: 10.1038/s41581-019-0197-5] [Cited by in Crossref: 43] [Cited by in F6Publishing: 38] [Article Influence: 14.3] [Reference Citation Analysis]
4 Panwar B, Gutiérrez OM. Disorders of Iron Metabolism and Anemia in Chronic Kidney Disease. Semin Nephrol 2016;36:252-61. [PMID: 27475656 DOI: 10.1016/j.semnephrol.2016.05.002] [Cited by in Crossref: 34] [Cited by in F6Publishing: 25] [Article Influence: 8.5] [Reference Citation Analysis]
5 Hsieh YP, Huang CH, Lee CY, Chen HL, Lin CY, Chang CC. Hepcidin-25 negatively predicts left ventricular mass index in chronic kidney disease patients. World J Nephrol 2013; 2(2): 38-43 [PMID: 24175264 DOI: 10.5527/wjn.v2.i2.38] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
6 Fernández-Ruiz M, Parra P, Ruiz-Merlo T, López-Medrano F, San Juan R, Polanco N, González E, Andrés A, Aguado JM. Association between baseline serum hepcidin levels and infection in kidney transplant recipients: Potential role for iron overload. Transpl Infect Dis 2018;20. [PMID: 29120522 DOI: 10.1111/tid.12807] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
7 Aregbesola A, Voutilainen S, Virtanen JK, Aregbesola A, Tuomainen TP. Serum hepcidin concentrations and type 2 diabetes. World J Diabetes 2015; 6(7): 978-982 [PMID: 26185605 DOI: 10.4239/wjd.v6.i7.978] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
8 Gummer J, Trengove R, Pascoe EM, Badve SV, Cass A, Clarke P, McDonald SP, Morrish AT, Pedagogos E, Perkovic V, Reidlinger D, Scaria A, Walker R, Vergara LA, Hawley CM, Johnson DW, Olynyk JK, Ferrari P; HERO Study Collaborative Group. Association between serum hepcidin-25 and primary resistance to erythropoiesis-stimulating agents in chronic kidney disease: a secondary analysis of the HERO trial. Nephrology (Carlton) 2017;22:548-54. [PMID: 27171136 DOI: 10.1111/nep.12815] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
9 Peters HP, Laarakkers CM, Pickkers P, Masereeuw R, Boerman OC, Eek A, Cornelissen EA, Swinkels DW, Wetzels JF. Tubular reabsorption and local production of urine hepcidin-25. BMC Nephrol 2013;14:70. [PMID: 23531037 DOI: 10.1186/1471-2369-14-70] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 2.2] [Reference Citation Analysis]
10 Kroot JJ, Tjalsma H, Fleming RE, Swinkels DW. Hepcidin in human iron disorders: diagnostic implications. Clin Chem. 2011;57:1650-1669. [PMID: 21989113 DOI: 10.1373/clinchem.2009.140053] [Cited by in Crossref: 153] [Cited by in F6Publishing: 148] [Article Influence: 13.9] [Reference Citation Analysis]
11 Emans ME, van der Putten K, van Rooijen KL, Kraaijenhagen RJ, Swinkels D, van Solinge WW, Cramer MJ, Doevendans PA, Braam B, Gaillard CA. Determinants of red cell distribution width (RDW) in cardiorenal patients: RDW is not related to erythropoietin resistance. J Card Fail 2011;17:626-33. [PMID: 21807323 DOI: 10.1016/j.cardfail.2011.04.009] [Cited by in Crossref: 43] [Cited by in F6Publishing: 39] [Article Influence: 3.9] [Reference Citation Analysis]
12 Larson DS, Coyne DW. Understanding and exploiting hepcidin as an indicator of anemia due to chronic kidney disease. Kidney Res Clin Pract 2013;32:11-5. [PMID: 26894030 DOI: 10.1016/j.krcp.2013.01.001] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
13 Chen MX, Kuehne N, Mattman A, Liu J, Van der Gugten G, Wright B. Clinical interpretation of serum hepcidin-25 in inflammation and renal dysfunction. Journal of Mass Spectrometry and Advances in the Clinical Lab 2022;24:43-9. [DOI: 10.1016/j.jmsacl.2022.03.002] [Reference Citation Analysis]
14 Bârsan L, Stanciu A, Stancu S, Căpuşă C, Brătescu L, Mandache E, Radu E, Mircescu G. Bone marrow iron distribution, hepcidin, and ferroportin expression in renal anemia. Hematology 2015;20:543-52. [PMID: 25745821 DOI: 10.1179/1607845415Y.0000000004] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 1.9] [Reference Citation Analysis]
15 Goyal H, Mohanty S, Sharma M, Rani A. Study of anemia in nondialysis dependent chronic kidney disease with special reference to serum hepcidin. Indian J Nephrol 2017;27:44-50. [PMID: 28182038 DOI: 10.4103/0971-4065.179301] [Cited by in Crossref: 5] [Article Influence: 1.0] [Reference Citation Analysis]
16 Ramanathan G, Olynyk JK, Ferrari P. Diagnosing and preventing iron overload. Hemodial Int 2017;21 Suppl 1:S58-67. [PMID: 28328144 DOI: 10.1111/hdi.12555] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
17 Yayar Ö, Eser B, Kılıç H. Relation between high serum hepcidin-25 level and subclinical atherosclerosis and cardiovascular mortality in hemodialysis patients. Anatol J Cardiol 2018;19:117-22. [PMID: 29339674 DOI: 10.14744/AnatolJCardiol.2017.8019] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
18 Locatelli F, Fishbane S, Block GA, Macdougall IC. Targeting Hypoxia-Inducible Factors for the Treatment of Anemia in Chronic Kidney Disease Patients. Am J Nephrol 2017;45:187-99. [PMID: 28118622 DOI: 10.1159/000455166] [Cited by in Crossref: 62] [Cited by in F6Publishing: 55] [Article Influence: 12.4] [Reference Citation Analysis]
19 Tessitore N, Poli A, Bedogna V, Corazza L, Campostrini N, Atti M, Sereni L, Castagna A, Girelli D, Pessolano G, Lupo A. A single dialysis session of hemodiafiltration with sorbent-regenerated endogenous ultrafiltrate reinfusion (HFR) removes hepcidin more efficiently than bicarbonate hemodialysis: a new approach to containing hepcidin burden in dialysis patients? J Nephrol 2018;31:297-306. [PMID: 28353202 DOI: 10.1007/s40620-017-0383-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
20 van der Weerd NC, Grooteman MP, Bots ML, van den Dorpel MA, den Hoedt CH, Mazairac AH, Nubé MJ, Penne EL, Gaillard CA, Wetzels JF, Wiegerinck ET, Swinkels DW, Blankestijn PJ, Ter Wee PM; CONTRAST Investigators. Hepcidin-25 in chronic hemodialysis patients is related to residual kidney function and not to treatment with erythropoiesis stimulating agents. PLoS One 2012;7:e39783. [PMID: 22808058 DOI: 10.1371/journal.pone.0039783] [Cited by in Crossref: 40] [Cited by in F6Publishing: 34] [Article Influence: 4.0] [Reference Citation Analysis]
21 Laarakkers CM, Wiegerinck ET, Klaver S, Kolodziejczyk M, Gille H, Hohlbaum AM, Tjalsma H, Swinkels DW. Improved mass spectrometry assay for plasma hepcidin: detection and characterization of a novel hepcidin isoform. PLoS One 2013;8:e75518. [PMID: 24124495 DOI: 10.1371/journal.pone.0075518] [Cited by in Crossref: 64] [Cited by in F6Publishing: 61] [Article Influence: 7.1] [Reference Citation Analysis]
22 Gharekhani A, Khatami MR, Dashti-Khavidaki S, Razeghi E, Abdollahi A, Hashemi-Nazari SS, Mansournia MA. Potential effects of omega-3 fatty acids on anemia and inflammatory markers in maintenance hemodialysis patients. Daru 2014;22:11. [PMID: 24397938 DOI: 10.1186/2008-2231-22-11] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
23 Lee SW, Kim JM, Lim HJ, Hwang YH, Kim SW, Chung W, Oh KH, Ahn C, Lee KB, Sung SA. Serum hepcidin may be a novel uremic toxin, which might be related to erythropoietin resistance. Sci Rep 2017;7:4260. [PMID: 28652624 DOI: 10.1038/s41598-017-04664-y] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 3.4] [Reference Citation Analysis]
24 Gaillard CA, Bock AH, Carrera F, Eckardt KU, Van Wyck DB, Bansal SS, Cronin M, Meier Y, Larroque S, Roger SD, Macdougall IC. Hepcidin Response to Iron Therapy in Patients with Non-Dialysis Dependent CKD: An Analysis of the FIND-CKD Trial. PLoS One 2016;11:e0157063. [PMID: 27276035 DOI: 10.1371/journal.pone.0157063] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 3.2] [Reference Citation Analysis]
25 Šimetić L, Zibar L. Laboratory use of hepcidin in renal transplant recipients. Biochem Med (Zagreb) 2016;26:34-52. [PMID: 26981017 DOI: 10.11613/BM.2016.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
26 Haase-fielitz A, Plaß M, Kuppe H, Hetzer R, Ostland V, Westphal S, Hoffmann J, Prowle J, Mertens PR, Westerman M, Bellomo R, Haase M. Low preoperative hepcidin concentration as a risk factor for mortality after cardiac surgery: A pilot study. The Journal of Thoracic and Cardiovascular Surgery 2013;145:1380-6. [DOI: 10.1016/j.jtcvs.2012.09.003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
27 Stefánsson BV, Abramson M, Nilsson U, Haraldsson B. Hemodiafiltration improves plasma 25-hepcidin levels: a prospective, randomized, blinded, cross-over study comparing hemodialysis and hemodiafiltration. Nephron Extra 2012;2:55-65. [PMID: 22619668 DOI: 10.1159/000336482] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
28 Vela D. Systemic and local hepcidin as emerging and important peptides in renal homeostasis and pathology. Biofactors 2019;45:118-34. [PMID: 30461080 DOI: 10.1002/biof.1468] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
29 Rochette L, Gudjoncik A, Guenancia C, Zeller M, Cottin Y, Vergely C. The iron-regulatory hormone hepcidin: A possible therapeutic target? Pharmacology & Therapeutics 2015;146:35-52. [DOI: 10.1016/j.pharmthera.2014.09.004] [Cited by in Crossref: 44] [Cited by in F6Publishing: 40] [Article Influence: 6.3] [Reference Citation Analysis]
30 Dopsaj V, Topić A, Savković M, Milinković N, Novaković I, Ćujić D, Simić-Ogrizović S. Associations of Common Variants in HFE and TMPRSS6 Genes with Hepcidin-25 and Iron Status Parameters in Patients with End-Stage Renal Disease. Dis Markers 2019;2019:4864370. [PMID: 30984307 DOI: 10.1155/2019/4864370] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
31 Chand S, Ward DG, Ng ZY, Hodson J, Kirby H, Steele P, Rooplal I, Bantugon F, Iqbal T, Tselepis C, Drayson MT, Whitelegg A, Chowrimootoo M, Borrows R. Serum hepcidin-25 and response to intravenous iron in patients with non-dialysis chronic kidney disease. J Nephrol 2015;28:81-8. [PMID: 24687402 DOI: 10.1007/s40620-014-0083-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
32 Moulouel B, Houamel D, Delaby C, Tchernitchko D, Vaulont S, Letteron P, Thibaudeau O, Puy H, Gouya L, Beaumont C, Karim Z. Hepcidin regulates intrarenal iron handling at the distal nephron. Kidney Int. 2013;84:756-766. [PMID: 23615502 DOI: 10.1038/ki.2013.142] [Cited by in Crossref: 44] [Cited by in F6Publishing: 44] [Article Influence: 4.9] [Reference Citation Analysis]
33 Kali A, Yayar O, Erdogan B, Eser B, Buyukbakkal M, Ercan Z, Merhametsiz O, Haspulat A, Gök Oğuz E, Canbakan B, Ayli MD. Is hepcidin-25 a predictor of atherosclerosis in hemodialysis patients? Hemodial Int 2016;20:191-7. [PMID: 26374145 DOI: 10.1111/hdi.12355] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
34 Ho J, Reslerova M, Gali B, Gao A, Bestland J, Rush DN, Nickerson PW, Rigatto C. Urinary hepcidin-25 and risk of acute kidney injury following cardiopulmonary bypass. Clin J Am Soc Nephrol 2011;6:2340-6. [PMID: 21885789 DOI: 10.2215/CJN.01000211] [Cited by in Crossref: 41] [Cited by in F6Publishing: 21] [Article Influence: 3.7] [Reference Citation Analysis]
35 Kroot JJ, Laarakkers CM, Geurts-moespot AJ, Grebenchtchikov N, Pickkers P, van Ede AE, Peters HP, van Dongen-lases E, Wetzels JF, Sweep FC, Tjalsma H, Swinkels DW. Immunochemical and Mass-Spectrometry–Based Serum Hepcidin Assays for Iron Metabolism Disorders. Clinical Chemistry 2010;56:1570-9. [DOI: 10.1373/clinchem.2010.149187] [Cited by in Crossref: 142] [Cited by in F6Publishing: 146] [Article Influence: 11.8] [Reference Citation Analysis]
36 Niikura T, Maruyama Y, Nakashima S, Matsuo N, Tanno Y, Ohkido I, Yokoyama K, Yamamoto H, Yokoo T. Hepcidin/Ferritin Ratios Differ Among Non-Dialyzed Chronic Kidney Disease Patients, and Patients on Hemodialysis and Peritoneal Dialysis. Ther Apher Dial 2019;23:341-6. [PMID: 30411489 DOI: 10.1111/1744-9987.12773] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
37 Takasawa K, Takaeda C, Maeda T, Ueda N. Hepcidin-25, mean corpuscular volume, and ferritin as predictors of response to oral iron supplementation in hemodialysis patients. Nutrients 2014;7:103-18. [PMID: 25551249 DOI: 10.3390/nu7010103] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
38 Macdougall IC, Bock AH, Carrera F, Eckardt KU, Gaillard C, Wyck DV, Meier Y, Larroque S, Perrin A, Roger SD. Erythropoietic response to oral iron in patients with nondialysis-dependent chronic kidney disease in the FIND-CKD trial
. Clin Nephrol 2017;88:301-10. [PMID: 29092739 DOI: 10.5414/CN109198] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
39 Babitt JL, Lin HY. Molecular mechanisms of hepcidin regulation: implications for the anemia of CKD. Am J Kidney Dis. 2010;55:726-741. [PMID: 20189278 DOI: 10.1053/j.ajkd.2009.12.030] [Cited by in Crossref: 132] [Cited by in F6Publishing: 118] [Article Influence: 11.0] [Reference Citation Analysis]
40 Besarab A, Szczech L. What are the Considerations in Balancing Benefits and Risks in Iron Treatment?: How Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitors May Change Iron Management in End-Stage Renal Disease. Semin Dial 2017;30:29-31. [PMID: 27699882 DOI: 10.1111/sdi.12553] [Reference Citation Analysis]
41 Coyne DW. Hepcidin: clinical utility as a diagnostic tool and therapeutic target. Kidney International 2011;80:240-4. [DOI: 10.1038/ki.2011.141] [Cited by in Crossref: 55] [Cited by in F6Publishing: 42] [Article Influence: 5.0] [Reference Citation Analysis]
42 Chan W, G. Ward D, Mcclean A, A. Bosch J, Jones D, Kaur O, Drayson M, Whitelegg A, Iqbal T, Mcternan PG, Tselepis C, Borrows R. The Role of Hepcidin-25 in Kidney Transplantation. Transplantation 2013;95:1390-5. [DOI: 10.1097/tp.0b013e31828d8489] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
43 Laller S, Patel S, Haldar D. Role of Serum and Urinary Hepcidin in Young Females of Reproductive Age in North India. J Lab Physicians. [DOI: 10.1055/s-0041-1735585] [Reference Citation Analysis]
44 Tan TC, Crawford DH, Franklin ME, Jaskowski LA, Macdonald GA, Jonsson JR, Watson MJ, Taylor PJ, Fletcher LM. The serum hepcidin:ferritin ratio is a potential biomarker for cirrhosis. Liver Int. 2012;32:1391-1399. [PMID: 22676252 DOI: 10.1111/j.1478-3231.2012.02828.x] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 3.3] [Reference Citation Analysis]
45 Uehata T, Tomosugi N, Shoji T, Sakaguchi Y, Suzuki A, Kaneko T, Okada N, Yamamoto R, Nagasawa Y, Kato K, Isaka Y, Rakugi H, Tsubakihara Y. Serum hepcidin-25 levels and anemia in non-dialysis chronic kidney disease patients: a cross-sectional study. Nephrol Dial Transplant 2012;27:1076-83. [PMID: 21799206 DOI: 10.1093/ndt/gfr431] [Cited by in Crossref: 41] [Cited by in F6Publishing: 33] [Article Influence: 3.7] [Reference Citation Analysis]
46 Eguchi A, Mochizuki T, Tsukada M, Kataoka K, Hamaguchi Y, Oguni S, Nitta K, Tsuchiya K. Serum hepcidin levels and reticulocyte hemoglobin concentrations as indicators of the iron status of peritoneal dialysis patients. Int J Nephrol 2012;2012:239476. [PMID: 23193472 DOI: 10.1155/2012/239476] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
47 Palaneeswari M S, Ganesh M, Karthikeyan T, Devi AJ, Mythili SV. Hepcidin-minireview.J Clin Diagn Res. 2013;7:1767-1771. [PMID: 24086909 DOI: 10.7860/JCDR/2013/6420.3273] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 0.2] [Reference Citation Analysis]
48 Antunes SA, Vilela RQ, Vaz JD, Canziani ME. Pentoxifylline does not alter the concentration of hepcidin in chronic kidney disease patients undergoing hemodialysis. Int J Artif Organs 2014;37:521-8. [PMID: 25044383 DOI: 10.5301/ijao.5000340] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
49 Malyszko J, Malyszko JS, Matuszkiewicz-Rowinska J. Hepcidin as a therapeutic target for anemia and inflammation associated with chronic kidney disease. Expert Opin Ther Targets 2019;23:407-21. [PMID: 30907175 DOI: 10.1080/14728222.2019.1599358] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
50 Agarwal AK. Iron metabolism and management: focus on chronic kidney disease. Kidney Int Suppl (2011) 2021;11:46-58. [PMID: 33777495 DOI: 10.1016/j.kisu.2020.12.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
51 Nakanishi T, Kuragano T. Potential hazards of recent trends in liberal iron use for renal anemia. Clin Kidney J 2021;14:59-69. [PMID: 33564406 DOI: 10.1093/ckj/sfaa117] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
52 Ali TM, Genina AM, Abo-salem OM. The determinants of hepcidin level in chronic kidney disease and hemodialysis Saudi patients. Beni-Suef University Journal of Basic and Applied Sciences 2014;3:133-9. [DOI: 10.1016/j.bjbas.2014.05.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
53 van Santen S, van Dongen-Lases EC, de Vegt F, Laarakkers CM, van Riel PL, van Ede AE, Swinkels DW. Hepcidin and hemoglobin content parameters in the diagnosis of iron deficiency in rheumatoid arthritis patients with anemia. Arthritis Rheum 2011;63:3672-80. [PMID: 22127690 DOI: 10.1002/art.30623] [Cited by in Crossref: 71] [Cited by in F6Publishing: 71] [Article Influence: 7.1] [Reference Citation Analysis]
54 Hohaus S, Massini G, Giachelia M, Vannata B, Bozzoli V, Cuccaro A, D'Alo' F, Larocca LM, Raymakers RA, Swinkels DW, Voso MT, Leone G. Anemia in Hodgkin's lymphoma: the role of interleukin-6 and hepcidin. J Clin Oncol 2010;28:2538-43. [PMID: 20406921 DOI: 10.1200/JCO.2009.27.6873] [Cited by in Crossref: 58] [Cited by in F6Publishing: 28] [Article Influence: 4.8] [Reference Citation Analysis]
55 Casimiro de Almeida J, Lou-Meda R, Olbert M, Seifert M, Weiss G, Wiegerinck ET, Swinkels DW, Solomons NW, Schümann K. The Growth Attainment, Hematological, Iron Status and Inflammatory Profile of Guatemalan Juvenile End-Stage Renal Disease Patients. PLoS One 2015;10:e0140062. [PMID: 26445018 DOI: 10.1371/journal.pone.0140062] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
56 Mercadal L, Metzger M, Haymann JP, Thervet E, Boffa JJ, Flamant M, Vrtovsnik F, Houillier P, Froissart M, Stengel B; NephroTest Study Group. The relation of hepcidin to iron disorders, inflammation and hemoglobin in chronic kidney disease. PLoS One 2014;9:e99781. [PMID: 24978810 DOI: 10.1371/journal.pone.0099781] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 3.8] [Reference Citation Analysis]
57 Savković M, Simić-Ogrizović S, Dopsaj V. Factors associated with hepcidin-25 levels in maintenance hemodialysis patients. Ther Apher Dial 2021;25:565-74. [PMID: 33403761 DOI: 10.1111/1744-9987.13617] [Reference Citation Analysis]
58 Darshan D, Frazer DM, Anderson GJ. Molecular basis of iron-loading disorders. Expert Rev Mol Med 2010;12:e36. [PMID: 21054916 DOI: 10.1017/S1462399410001687] [Cited by in Crossref: 36] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
59 Brătescu LO, Bârsan L, Gârneaţă L, Stanciu A, Lipan M, Stancu SH, Mircescu G. Effects of additional iron doses on hepcidin-25 level in hemodialysis patients without evident iron deficiency. Int Urol Nephrol 2014;46:1005-12. [PMID: 24800994 DOI: 10.1007/s11255-014-0696-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
60 Girelli D, Nemeth E, Swinkels DW. Hepcidin in the diagnosis of iron disorders.Blood. 2016;127:2809-2813. [PMID: 27044621 DOI: 10.1182/blood-2015-12-639112] [Cited by in Crossref: 200] [Cited by in F6Publishing: 185] [Article Influence: 33.3] [Reference Citation Analysis]
61 van der Weerd NC, Grooteman MP, Bots ML, van den Dorpel MA, den Hoedt CH, Mazairac AH, Nubé MJ, Penne EL, Wetzels JF, Wiegerinck ET, Swinkels DW, Blankestijn PJ, Ter Wee PM; CONTRAST Investigators. Hepcidin-25 is related to cardiovascular events in chronic haemodialysis patients. Nephrol Dial Transplant 2013;28:3062-71. [PMID: 23147161 DOI: 10.1093/ndt/gfs488] [Cited by in Crossref: 47] [Cited by in F6Publishing: 45] [Article Influence: 4.7] [Reference Citation Analysis]
62 Prowle JR, Ostland V, Calzavacca P, Licari E, Ligabo E, Echeverri JE, Bagshaw SM, Haase-fielitz A, Haase M, Westerman M, Bellomo R. Greater increase in urinary hepcidin predicts protection from acute kidney injury after cardiopulmonary bypass. Nephrology Dialysis Transplantation 2012;27:595-602. [DOI: 10.1093/ndt/gfr387] [Cited by in Crossref: 31] [Cited by in F6Publishing: 34] [Article Influence: 2.8] [Reference Citation Analysis]
63 Nalado AM, Olorunfemi G, Dix-Peek T, Dickens C, Khambule L, Snyman T, Paget G, Mahlangu J, Duarte R, George J, Naicker S. Hepcidin and GDF-15 are potential biomarkers of iron deficiency anaemia in chronic kidney disease patients in South Africa. BMC Nephrol 2020;21:415. [PMID: 32993549 DOI: 10.1186/s12882-020-02046-7] [Reference Citation Analysis]
64 Brătescu LO, Bârsan L, Munteanu D, Stancu S, Mircescu G. Is Hepcidin-25 a Clinically Relevant Parameter for the Iron Status in Hemodialysis Patients? Journal of Renal Nutrition 2010;20:S77-83. [DOI: 10.1053/j.jrn.2010.06.006] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
65 Troutt JS, Butterfield AM, Konrad RJ. Hepcidin-25 concentrations are markedly increased in patients with chronic kidney disease and are inversely correlated with estimated glomerular filtration rates. J Clin Lab Anal 2013;27:504-10. [PMID: 24218134 DOI: 10.1002/jcla.21634] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 2.5] [Reference Citation Analysis]
66 Kato A. Increased hepcidin-25 and erythropoietin responsiveness in patients with cardio–renal anemia syndrome. Future Cardiology 2010;6:769-71. [DOI: 10.2217/fca.10.97] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
67 Bek SG, Üstüner B, Eren N, Sentürk Z, Gönüllü BK. The effect of hepcidin on components of metabolic syndrome in chronic kidney disease: a cross-sectional study. Rev Assoc Med Bras (1992) 2020;66:1100-7. [PMID: 32935805 DOI: 10.1590/1806-9282.66.8.1100] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
68 Zaritsky J, Young B, Gales B, Wang HJ, Rastogi A, Westerman M, Nemeth E, Ganz T, Salusky IB. Reduction of serum hepcidin by hemodialysis in pediatric and adult patients. Clin J Am Soc Nephrol 2010;5:1010-4. [PMID: 20299375 DOI: 10.2215/CJN.08161109] [Cited by in Crossref: 62] [Cited by in F6Publishing: 26] [Article Influence: 5.2] [Reference Citation Analysis]
69 Macdougall IC, Malyszko J, Hider RC, Bansal SS. Current Status of the Measurement of Blood Hepcidin Levels in Chronic Kidney Disease: Table 1. CJASN 2010;5:1681-9. [DOI: 10.2215/cjn.05990809] [Cited by in Crossref: 53] [Cited by in F6Publishing: 20] [Article Influence: 4.4] [Reference Citation Analysis]
70 Galesloot TE, Vermeulen SH, Geurts-Moespot AJ, Klaver SM, Kroot JJ, van Tienoven D, Wetzels JF, Kiemeney LA, Sweep FC, den Heijer M, Swinkels DW. Serum hepcidin: reference ranges and biochemical correlates in the general population. Blood. 2011;117:e218-e225. [PMID: 21527524 DOI: 10.1182/blood-2011-02-337907] [Cited by in Crossref: 178] [Cited by in F6Publishing: 172] [Article Influence: 16.2] [Reference Citation Analysis]
71 Peters HP, Laarakkers CM, Wetzels JF, Swinkels DW. Hepcidin levels in patients with renal disease. Kidney Int. 2009;76:680; author reply 680-681. [PMID: 19721430 DOI: 10.1038/ki.2009.238] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
72 Peters HP, Rumjon A, Bansal SS, Laarakkers CM, van den Brand JA, Sarafidis P, Musto R, Malyszko J, Swinkels DW, Wetzels JF, Macdougall IC. Intra-individual variability of serum hepcidin-25 in haemodialysis patients using mass spectrometry and ELISA. Nephrology Dialysis Transplantation 2012;27:3923-9. [DOI: 10.1093/ndt/gfs164] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
73 Kuragano T, Furuta M, Shimonaka Y, Kida A, Yahiro M, Otaki Y, Hasuike Y, Matsumoto A, Nakanishi T. The removal of serum hepcidin by different dialysis membranes. Int J Artif Organs 2013;36:633-9. [PMID: 23918276 DOI: 10.5301/ijao.5000221] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
74 Putera EM, Widodo W, Mardiana N. C-reactive Protein and Hepcidin in Non-Dialysis Chronic Kidney Disease. IJTID 2020;8:161. [DOI: 10.20473/ijtid.v8i3.12226] [Reference Citation Analysis]
75 Hung C, Yu P, Niu S, Kuo I, Lee J, Shen F, Chang J, Hwang S. Association between Body Mass Index and Renal Outcomes Modified by Chronic Kidney Disease and Anemia: The Obesity Paradox for Renal Outcomes. JCM 2022;11:2787. [DOI: 10.3390/jcm11102787] [Reference Citation Analysis]
76 Tessitore N, Girelli D, Campostrini N, Bedogna V, Pietro Solero G, Castagna A, Melilli E, Mantovani W, De Matteis G, Olivieri O, Poli A, Lupo A. Hepcidin is not useful as a biomarker for iron needs in haemodialysis patients on maintenance erythropoiesis-stimulating agents. Nephrology Dialysis Transplantation 2010;25:3996-4002. [DOI: 10.1093/ndt/gfq321] [Cited by in Crossref: 65] [Cited by in F6Publishing: 55] [Article Influence: 5.4] [Reference Citation Analysis]